Julia Marie Eastland - 24 Jan 2023 Form 4 Insider Report for Harpoon Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ Frank Lanza, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 24 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2023, 15:05:00 UTC
Previous filing: 03 Jun 2022
Next filing: 27 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HARP	Employee Stock Option (right to buy)	Award	$0	+407,600		$0.000000	407,600	24 Jan 2023	Common Stock	407,600	$0.8900	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of 203,800 stock option, representing one-half of the total option grant, will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 24, 2023 (the "VCD"), and 25% of 203,800 stock option, representing the second one-half of the total option grant, will vest and become exercisable every six months following the VCD, all subject to the continuing employment of the Reporting Person on each vesting date.

Content

1/48th of 203,800 stock option, representing one-half of the total option grant, will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 24, 2023 (the "VCD"), and 25% of 203,800 stock option, representing the second one-half of the total option grant, will vest and become exercisable every six months following the VCD, all subject to the continuing employment of the Reporting Person on each vesting date.